AMGN Amgen

  • AMGN
  • Price as of: Oct 06, 09:51 PM EDT
  • $141.22
  • -$2.58
  • -1.8%
  • Industry
  • Biotechnology

AMGN Stock Dividend Data

Add AMGN to Watchlist
  • Dividend Yield
    2.24% Healthcare Average 2.29%
  • Annual Payout
    $3.16 Paid Quarterly
  • Payout Ratio
    32.4% EPS $9.74
  • Dividend Growth
    4 yrs Since 2011
  • Get AMGN DARS™ Rating
DARS Rating™ Breakdown DARS Rating™ Breakdown for AMGN

Sign Up
Metric AMGN Rank AMGN Avg Ranking Notes
Relative Strength Sign Up For Ticker Ranking Sign Up For Sector Ranking 1 year return is slightly above Benchmark/Peers/Broader Market/Analyst Expectations
Overall Yield Attractiveness Sign Up For Ticker Ranking Sign Up For Sector Ranking Yield is at par with Benchmark/Peers/Broader Market/Analyst Expectations
Dividend Reliability Sign Up For Ticker Ranking Sign Up For Sector Ranking Payout ratio is considerably higher than industry average and peers
Dividend Uptrend Sign Up For Ticker Ranking Sign Up For Sector Ranking Dividends are above average, growing as per Benchmark/Peers/Broader Market/Analyst Expectations
Earnings Growth Sign Up For Ticker Ranking Sign Up For Sector Ranking EPS growth is at par with Benchmark/Peers/Broader Market/Analyst Expectations
DARS Rating Sign Up For Ticker Ranking Sign Up For Sector Ranking Sign Up For DARS Ratings
Growth History

AMGN Dividend Growth History

Annualized Growth
Annualized Growth
Annualized Growth
Annualized Growth
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Years of
Reveal More Dividend Growth History for AMGN 63.3% 29.8% 4 years
Reveal More Dividend Growth History for AMGN
Historical Annual Dividend Data & Growth

AMGN Historical Annual Dividend Data & Growth

Payout Amount Calendar Year Annual Growth
$2.4400 2014 29.8%
$1.8800 2013 30.6%
Historical Dividend Data

AMGN Dividend History

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.7900 2015-07-28 2015-08-13 2015-08-17 2015-09-08 Yes Regular Quarter
$0.7900 2015-03-04 2015-05-12 2015-05-14 2015-06-05 Yes Regular Quarter
$0.7900 2014-12-17 2015-02-10 2015-02-12 2015-03-06 Yes Regular Quarter
$0.6100 2014-10-17 2014-11-10 2014-11-13 2014-12-05 Yes Regular Quarter
$0.6100 2014-07-25 2014-08-12 2014-08-14 2014-09-05 Yes Regular Quarter
$0.6100 2014-03-05 2014-05-13 2014-05-15 2014-06-06 Yes Regular Quarter
$0.6100 2013-12-13 2014-02-11 2014-02-13 2014-03-07 Yes Regular Quarter
$0.4700 2013-10-16 2013-11-12 2013-11-14 2013-12-06 Yes Regular Quarter
$0.4700 2013-07-26 2013-08-14 2013-08-16 2013-09-06 Yes Regular Quarter
$0.4700 2013-03-06 2013-05-14 2013-05-16 2013-06-07 Yes Regular Quarter
$0.4700 2012-12-13 2013-02-11 2013-02-13 2013-03-07 Yes Regular Quarter
$0.3600 2012-10-11 2012-11-13 2012-11-15 2012-12-07 Yes Regular Quarter
$0.3600 2012-07-19 2012-08-14 2012-08-16 2012-09-07 Yes Regular Quarter
$0.3600 2012-03-15 2012-05-14 2012-05-16 2012-06-07 Yes Regular Quarter
$0.3600 2011-12-15 2012-02-13 2012-02-15 2012-03-07 Yes Regular Quarter
$0.2800 2011-10-13 2011-11-15 2011-11-17 2011-12-08 Yes Regular Quarter
$0.2800 2011-07-28 2011-08-16 2011-08-18 2011-09-08 Yes Regular Quarter
2-for-1 1999-10-20 1999-11-22 1999-11-05 1999-11-19 NM Stock Split NM
2-for-1 1999-01-28 1999-03-01 1999-02-12 1999-02-26 NM Stock Split NM
$0.0002 1997-02-19 1997-03-24 1997-03-21 1997-03-21 Unknown Unknown unknown
2-for-1 1995-07-20 1995-08-16 1995-08-01 1995-08-15 NM Stock Split NM
Company Profile

AMGN Company Profile

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology

Amgen (AMGN) - this company discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

High Yield Stocks

High Yield Stocks

Looking for dividend stocks with great yields? Visit our list of:

High Yield Dividend Stocks

Amgen News